-
First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment.
de Sousa MJR, Ribeiro R, Syngelaki A, Nicolaides KH.
Clin Rheumatol 2019;38:1251-1255. pdf -
Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems.
Neocleous AC, Syngelaki A, Nicolaides KH, Schizas CN.
Ultrasound Obstet Gynecol 2018;51:503-508. pdf -
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
Analysis of Cell-Free DNA in Maternal Blood in Screening For Aneuploidies: Updated Meta-Analysis.
Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:302-314. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
Fetal fraction of cell-free DNA in maternal plasma in the prediction of spontaneous preterm delivery.
Quezada MS, Francisco C, Dumitrascu-Biris D, Nicolaides KH, Poon LC.
Ultrasound Obstet Gynecol 2015;45:101-5. pdf -
Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities.
Syngelaki A, Pergament E, Homfray T, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:174-84. pdf -
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies.
Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:34-40. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies.
Wright D, Syngelaki A, Birdir C, Bedei I, Nicolaides KH.
Fetal Diagn Ther 2011;30:194-202. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester.
Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K.
Ultrasound Obstet Gynecol 2011;37:38-47. -
Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester trisomy 21 maternal serum.
Lopez MF, Kuppusamy R, Sarracino DA, Prakash A, Athanas M, Krastins B, Rezai T, Sutton JN, Peterman S, Nicolaides K.
J Proteome Res 2011;10:133-42. -
Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study.
Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, Lun FM, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM.
BMJ 2011;342:c7401. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
First-trimester combined screening for trisomy 21 at 8-13 weeks.
Wright D, Spencer K, Kagan K, Tørring N, Petersen O, Christou A, Kallikas J, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:404-11. -
Synergy of Total PLAC4 RNA concentration and measurement of the RNA single-nucleotide polymorphism allelic ratio for the noninvasive prenatal detection of Trisomy 21.
Tsui NB, Akolekar R, Chiu RW, Chow KC, Leung TY, Lau TK, Nicolaides KH, Lo YM.
Clin Chem 2010;56:73-81. -
Epigenetic-genetic chromosome dosage approach for fetal trisomy 21 detection using an autosomal genetic reference marker.
Tong YK, Chiu RW, Akolekar R, Leung TY, Lau TK, Nicolaides KH, Lo YM.
PLoS One 2010;5:e15244.